1
|
Burneikaitė G, Shkolnik E, Puronaitė R, Zuozienė G, Petrauskienė B, Misonis N, Kazėnaitė E, Laucevičius A, Smih F, Rouet P, Čelutkienė J. The association of catestatin and endocan with the effects of cardiac shock wave therapy: Biomarker sub-study of the randomized, sham procedure-controlled trial. Front Cardiovasc Med 2023; 10:1004574. [PMID: 36910537 PMCID: PMC9996196 DOI: 10.3389/fcvm.2023.1004574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2022] [Accepted: 02/03/2023] [Indexed: 02/25/2023] Open
Abstract
Introduction Cardiac shock-wave therapy (CSWT) is a non-invasive regenerative treatment method based on low-frequency ultrasound waves, which stimulate angiogenesis. Current data about the effects of revascularization procedures on angiogenesis biomarkers is limited. Recently, an association of catestatin and endocan with coronary collateral development was shown in several trials. In this study, we aimed to evaluate the impact of CSWT on the dynamics of catestatin and endocan levels and to assess their correlation with parameters of myocardial perfusion and function. Methods Prospective, randomized, triple-blind, sham procedure-controlled study enrolled 72 adult subjects who complied with defined inclusion criteria (NCT02339454). We measured biomarkers in 48 patients with stable angina (24 patients of CSWT group, 24 patients of sham-procedure group). Additionally, patients were divided into responders and non-responders according to improvement in myocardial perfusion and/or contractility assessed by myocardial scintigraphy and dobutamine echocardiography (30 and 13 patients, respectively). The blood samples were collected at baseline, after the last treatment procedure (9th treatment week) and at 6-month follow-up to evaluate biomarkers concentration and stored at -80° until analysis. Serum catestatin and endocan levels were determined by commercially available ELISA kits. Results Serum catestatin concentration significantly increased in all patients. While endocan levels significantly decreased in the responders sub-group. The increase in catestatin levels at 9th week and 6 months was positively associated with improvement in summed difference score (rho = 0.356, p = 0.028) and wall motion score, WMS (rho = 0.397, p = 0.009) at 6 months in the whole study population. Meanwhile, the decrease in endocan levels over 6 months was positively correlated with improvement in WMS at 3- and 6- months (r = 0.378, p = 0.015 and r = 0.311, p = 0.045, respectively). ROC analysis revealed that a change at 6 months in catestatin and endocan levels significantly predicted improvement in myocardial perfusion and contractile function with 68.9% sensitivity and 75.0% specificity (p = 0.039) and 51.7% sensitivity, and 91.7% specificity (p = 0.017), respectively. Baseline endocan concentration and its change at 6 months predicted response to CSWT with 68.8% sensitivity and 83.3% specificity (p = 0.039) and 81.3% sensitivity and 100% specificity (p < 0.0001), respectively. Conclusion This study demonstrates the association of increase in catestatin and decrease in endocan levels with the improvement of myocardial perfusion and contractile function. The potential predictive value of catestatin and endocan dynamics for the response to regenerative therapy is shown.
Collapse
Affiliation(s)
- Greta Burneikaitė
- Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania
- Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
- LA Maison de la Mitochondrie (LAMMI), Obesity and Heart Failure: Molecular and Clinical Investigations, INSERM Occitanie, Toulouse, France
- *Correspondence: Greta Burneikaitė ✉
| | - Evgeny Shkolnik
- Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, United States
| | - Roma Puronaitė
- Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania
- Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
- Faculty of Mathematics and Informatics, Institute of Data Science and Digital Technologies, Vilnius University, Vilnius, Lithuania
| | - Gitana Zuozienė
- Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania
- Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
| | - Birutė Petrauskienė
- Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania
- Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
| | - Nerijus Misonis
- Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania
- Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
| | - Edita Kazėnaitė
- Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
- Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania
| | - Aleksandras Laucevičius
- Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania
- Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
| | - Fatima Smih
- INI-CRCT-FCRIN, GREAT Networks, Toulouse, France
- Spartacus-Biomed, Auterive, France
| | - Philippe Rouet
- LA Maison de la Mitochondrie (LAMMI), Obesity and Heart Failure: Molecular and Clinical Investigations, INSERM Occitanie, Toulouse, France
- INI-CRCT-FCRIN, GREAT Networks, Toulouse, France
| | - Jelena Čelutkienė
- Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania
- Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
- Centre of Innovative Medicine, Vilnius, Lithuania
| |
Collapse
|
2
|
De Freitas Caires N, Gaudet A, Portier L, Tsicopoulos A, Mathieu D, Lassalle P. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. CRITICAL CARE : THE OFFICIAL JOURNAL OF THE CRITICAL CARE FORUM 2018; 22:280. [PMID: 30367649 PMCID: PMC6204032 DOI: 10.1186/s13054-018-2222-7] [Citation(s) in RCA: 77] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Accepted: 10/05/2018] [Indexed: 12/29/2022]
Abstract
Acute respiratory distress syndrome (ARDS) and hospital-acquired pneumonia (HAP) are major problems of public health in intensive care units (ICUs), occurring in 15% of critically ill patients. Among the factors explaining ARDS development, sepsis is known as a frequent cause. Sepsis, ARDS, and HAP increase morbidity, mortality, length of stay in the ICU, and the overall costs of healthcare. The major challenge remains to identify accurately among critically ill patients those at risk of poor outcomes who could benefit from novel therapies. Endocan is released by the pulmonary endothelium in response to local or systemic injury. It inhibits mainly leukocyte diapedesis rather than leukocyte rolling or adhesion to the endothelial cells both in vitro and in vivo. Endocan was evaluated in 25 clinical reports, including 2454 critically ill patients and 452 healthy controls. The diagnostic value of endocan for sepsis or sepsis severity was equal to procalcitonin but its prognostic value was better. A predictive value for postoperative pneumonia was evidenced in two studies, and a predictive value for ARDS in four studies from three independent centers. This review presents an overview of the structure, expression, and functions of endocan. We also hereby summarize the potential applications of endocan in the prediction and prognosis of ARDS and HAP, as well as in the prognosis of sepsis.
Collapse
Affiliation(s)
- Nathalie De Freitas Caires
- University of Lille, U1019-UMR 8204-Center for Infection and Immunity of Lille, F-59000, Lille, France.,CNRS, UMR 8204, F-59000, Lille, France.,INSERM, U1019, F-59000, Lille, France.,Institut Pasteur de Lille, F-59000, Lille, France.,Lunginnov, 1 rue du Pr Calmette, F-59000, Lille, France
| | - Alexandre Gaudet
- University of Lille, U1019-UMR 8204-Center for Infection and Immunity of Lille, F-59000, Lille, France. .,CNRS, UMR 8204, F-59000, Lille, France. .,INSERM, U1019, F-59000, Lille, France. .,Institut Pasteur de Lille, F-59000, Lille, France. .,CHU Lille, Pôle de Réanimation, Hôpital Roger Salengro, F-59000, Lille, France.
| | - Lucie Portier
- University of Lille, U1019-UMR 8204-Center for Infection and Immunity of Lille, F-59000, Lille, France.,CNRS, UMR 8204, F-59000, Lille, France.,INSERM, U1019, F-59000, Lille, France.,Institut Pasteur de Lille, F-59000, Lille, France.,Lunginnov, 1 rue du Pr Calmette, F-59000, Lille, France
| | - Anne Tsicopoulos
- University of Lille, U1019-UMR 8204-Center for Infection and Immunity of Lille, F-59000, Lille, France.,CNRS, UMR 8204, F-59000, Lille, France.,INSERM, U1019, F-59000, Lille, France.,Institut Pasteur de Lille, F-59000, Lille, France.,CHRU de Lille, Clinique des maladies respiratoires, Hôpital Calmette, F-59000, Lille, France
| | - Daniel Mathieu
- University of Lille, U1019-UMR 8204-Center for Infection and Immunity of Lille, F-59000, Lille, France.,CNRS, UMR 8204, F-59000, Lille, France.,INSERM, U1019, F-59000, Lille, France.,Institut Pasteur de Lille, F-59000, Lille, France.,CHU Lille, Pôle de Réanimation, Hôpital Roger Salengro, F-59000, Lille, France
| | - Philippe Lassalle
- University of Lille, U1019-UMR 8204-Center for Infection and Immunity of Lille, F-59000, Lille, France.,CNRS, UMR 8204, F-59000, Lille, France.,INSERM, U1019, F-59000, Lille, France.,Institut Pasteur de Lille, F-59000, Lille, France.,Lunginnov, 1 rue du Pr Calmette, F-59000, Lille, France
| |
Collapse
|